Ferric Carboxymaltose Injection [Ferinject]
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Coronary Syndromes (ACS)
Conditions
Acute Coronary Syndromes (ACS), Iron Deficiencies, Elderly (People Aged 65 or More)
Trial Timeline
Mar 5, 2026 → May 1, 2028
NCT ID
NCT07476859About Ferric Carboxymaltose Injection [Ferinject]
Ferric Carboxymaltose Injection [Ferinject] is a approved stage product being developed by AstraZeneca for Acute Coronary Syndromes (ACS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07476859. Target conditions include Acute Coronary Syndromes (ACS), Iron Deficiencies, Elderly (People Aged 65 or More).
What happened to similar drugs?
20 of 20 similar drugs in Acute Coronary Syndromes (ACS) were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07476859 | Approved | Recruiting |
Competing Products
20 competing products in Acute Coronary Syndromes (ACS)